重药控股(000950) - 2025 Q2 - 季度业绩预告

Chongqing Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Performance Forecast This forecast outlines Chongqing Pharmaceutical Group's expected financial performance for the first half of 2025, projecting growth in key profitability metrics I. Expected Performance for the Current Period Chongqing Pharmaceutical Group anticipates year-over-year growth in net profit attributable to shareholders and net profit after deducting non-recurring gains and losses for H1 2025, alongside an increase in basic earnings per share (I) Performance Forecast Period This section specifies the exact timeframe covered by the semi-annual performance forecast - The performance forecast covers the period from January 1, 2025, to June 30, 2025[2] (II) Performance Forecast Details This section presents the specific financial projections for the company's semi-annual performance - The company anticipates a year-over-year increase in its 2025 semi-annual performance[2] Key Financial Indicators for 2025 Semi-Annual Performance Forecast | Indicator | Estimated for Current Period (RMB 10,000) | Prior Year Same Period (RMB 10,000) | Year-over-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | 26,000 — 30,000 | 23,808.86 | 9.2% — 26% | | Net Profit After Deducting Non-Recurring Gains and Losses | 25,000 — 28,000 | 21,854.67 | 14.39% — 28.12% | | Basic Earnings Per Share (RMB/share) | 0.15 — 0.17 | 0.14 | - | II. Communication with Accounting Firm The financial data included in this performance forecast has not yet undergone pre-audit by a certified public accountant - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[3] III. Explanation of Performance Changes The company's performance growth is primarily attributed to the implementation of its '14th Five-Year Plan' strategic initiatives, expanding diversified segmented businesses, optimizing network layout for revenue scale growth, and strengthening cost control to reduce operating and financing expenses - In line with its '14th Five-Year Plan' strategic initiatives, the company continues to develop diversified segmented businesses, including medical devices and reagents, traditional Chinese medicine health products, professional pharmacies, emerging businesses, and third-party reserves, building upon its core pharmaceutical sales[4] - Through both organic growth and external mergers and acquisitions, the company continuously improves its network layout, driving a corresponding increase in revenue scale[4] - The company has strengthened cost control, leading to a significant reduction in operating and administrative expenses and financing costs[4][5] IV. Other Related Information This performance forecast represents preliminary estimates, with final financial data subject to the 2025 semi-annual report, and investors are advised to be aware of investment risks - This performance forecast is a preliminary estimate by the company, and the specific financial data will be fully disclosed in the company's 2025 semi-annual report[6] - Investors are kindly reminded to exercise caution regarding investment risks[6]